局部作用的布塞索尼德载体固体自我微乳化药物输送系统 (SMEDDS) 用于远端性结肠炎
Hany S M Ali1,2, Ahmed F Hanafy3, Rawan Bafail1
1Department of Pharmaceutics and Pharmaceutical Industries, College of Pharmacy, Taibah University, Madinah, Al-Madinah Al-Munawwarah, Saudi Arabia.
International journal of nanomedicine
|November 19, 2024
概括
固体自我微乳化药物输送系统 (SMEDDS) 有效地为性结肠炎提供了布松胺 (BUD). 这些新的BUD-SMEDDS配方在动物模型中在治疗大肠炎方面表现出卓越的疗效.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 胃肠病学 胃肠病学
背景情况:
- 布德索尼德 (BUD) 具有较差的水溶性和较低的口服生物可用性,被归类为BCSII类药物.
- 性结肠炎 (UC) 需要有效的局部药物输送来对远端结肠进行管理.
研究的目的:
- 开发创新的固体自我微乳化药物输送系统 (BUD-SMEDDS),以改善本地输送布埃索尼德.
- 评估BUD-SMEDDS用于治疗性结肠炎的体外特征和体内疗效.
主要方法:
- 自行微乳化药物输送系统 (SMEDDS) 组件 (CapryolTM 90,Tween 80,Transcutol HP) 通过使用Box-Behnken设计进行了优化.
- 在Lutrol®基中使用优化的SMEDDS准备了固体直肠配方.
- 在大肠炎大鼠模型中评估了体外表征和体内疗效.
主要成果:
- 优化的BUD-SMEDDS实现了小球体大小 (33 ± 2.9 nm),低PDI (0.29 ± 0.03) 和快速的自我乳化时间 (25 ± 2.5 秒).
- 配方表现出良好的物理性质,粘膜粘合和受控的药物释放.
- 在接受治疗的动物中观察到显著的临床和组织病理改善.
结论:
- 固体SMEDDS表现出作为budesonide载体的优越能力,用于管理远端结肠炎.
- 开发的BUD-SMEDDS为局部性性结肠炎治疗提供了一种有前途的方法.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
120
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
120
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
96
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96
Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
Drugs for Treatment of Constipation-Predominant IBS
136
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
136
Drug Delivery: Enteral Route
383
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
383
Drug Delivery: Miscellaneous Routes
328
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
328


